Celcuity Inc

Celcuity Inc. a clinical stage biotechnology company focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive HER2-negative and advanced or metastatic breast cancer. The company is also developing CELsignia MP test a qualitative laboratory developed test that measures HER2 c-Met and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis Minnesota.